Michael King
Stock Analyst at EF Hutton
(0.86)
# 4,030
Out of 5,130 analysts
107
Total ratings
36.52%
Success rate
-11.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $21.96 | +2,859.93% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.49 | +215.19% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.42 | +2,153.52% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.51 | +4,436.42% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $14.26 | +1,302.52% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.60 | +1,275.31% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $796.55 | +8.22% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $44.04 | -45.50% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.91 | +4,145.52% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $13.89 | +202.38% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $398.29 | -23.67% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $10.38 | +1,017.53% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.35 | +92.52% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $42.18 | -43.10% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $44.67 | +2.98% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $28.41 | +237.91% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.68 | +5,194.12% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $35.35 | -12.31% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $788.49 | -95.43% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $21.96
Upside: +2,859.93%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.49
Upside: +215.19%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.42
Upside: +2,153.52%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.51
Upside: +4,436.42%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $14.26
Upside: +1,302.52%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.60
Upside: +1,275.31%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $796.55
Upside: +8.22%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.04
Upside: -45.50%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.91
Upside: +4,145.52%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $13.89
Upside: +202.38%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $398.29
Upside: -23.67%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $10.38
Upside: +1,017.53%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.35
Upside: +92.52%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $42.18
Upside: -43.10%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $44.67
Upside: +2.98%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $28.41
Upside: +237.91%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.68
Upside: +5,194.12%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $35.35
Upside: -12.31%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $788.49
Upside: -95.43%